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Chapter 13
The Clinical Value of Cardiac PET in Heart
Failure
Chi-Lun Ko and Yen-Wen Wu
Abstract Heart failure (HF) is a complex clinical syndrome that results from any
structural or functional impairment of ventricular filling or ejection of blood [1].
Approximately 5 million patients in the USA and 15 million patients in Europe
have HF. It is the leading cause of hospitalization in elderly people. Despite
treatment advances, the mortality rate of HF has increased steadily. More patients
are surviving myocardial infarction (MI) due to better standards of care, and
consequently this may increase numbers of patients who subsequently develop
HF. HF places a significant burden on patients, carers, and healthcare systems.
Limited progress has been made in identifying evidence-based, effective treat-
ments for HF over the last decades. Potential contributors include an incomplete
understanding of pathophysiology and poor matching of therapeutic mechanisms.
Positron emission tomography (PET), as a molecular imaging technique, with
various tracers allows noninvasive evaluation of contractile function, myocardial
perfusion, metabolism, and innervation. Molecular imaging approaches using PET
could be further used to evaluate inflammation, angiogenesis, cell death, and
ventricular remodeling. It could provide new insights on the chemotherapy-related
cardiotoxicity and the roles of stem cell monitoring in living bodies for cell-based
therapy from preclinical studies to clinical trials. In conclusion, cardiac PET is a
promising tool to understand the physiologic consequences of HF, resulting in early
detection of patients with HF at risk, improvement of risk stratification, and
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therapeutic strategy planning and treatment response monitoring. Therefore, in
order to give the readers a brief and concise overview, we will mainly review the
latest advances in cardiac PET studies in heart failure.
Keywords Heart failure • Positron emission tomography • Myocardial perfusion •
Myocardial metabolism • Neuroautonomic system
13.1 Perfusion
13.1.1 Coronary Artery Disease (CAD) and Microvascular
Dysfunction
Patients presenting with HF are initially classified based on the etiology of their
disease, i.e., ischemic or nonischemic cardiomyopathy. The diagnosis of HF is clear
if prior MI is reliably documented. With the wide availability of single-photon
emission computed tomography (SPECT) cameras and perfusion tracers, SPECT is
currently the preferred imaging modality of cardiac radionuclide imaging with good
diagnostic accuracy and prognostic significance.
PET provides better image quality because of higher spatial resolution, less
scatter, and fewer attenuation artifacts and may be superior to SPECT with respect
to imaging quality, interpretative confidence, and inter-reader agreement. In addi-
tion, PET allows quantitative measurement of myocardial perfusion (MP) and
metabolism. Cardiac PET with perfusion tracers, such as [15O]-water, [13N]-ammo-
nia, 82rubidium, and [18F]-flurpiridaz [2], allows noninvasive and absolute assess-
ment of regional and global myocardial blood flow (MBF) in ml/min/g. In
conjunction with stress, regional and global coronary flow reserve (CFR) can also
be calculated, which is the ratio between MBF at peak stress and MBF at rest.
CFR measures not only vasodilator capacity but also endothelial reactivity of the
coronary circulation, allowing noninvasive quantitative assessment for patients
with diffuse coronary luminal narrowing or microvascular dysfunction.
Coronary microvascular dysfunction is highly prevalent among at-risk individ-
uals and is associated with adverse outcomes regardless of sex, even in the absence
of overt coronary atherosclerosis [3]. It may reflect the functional alteration of
endothelium, such as hypertension, dyslipidemia, diabetes mellitus, smoking, obe-
sity, or metabolic syndrome, or structural alteration of microangiopathy, myocar-
dial fibrosis, or loss of capillaries. The portion of HF consists predominantly of
older age and high prevalence of comorbidities. The systemic pro-inflammatory
state may induce coronary endothelial inflammation, microvascular dysfunction,
myocardial substrate shift, myocardial and interstitial fibrosis that contribute to
high diastolic left ventricular stiffness, and HF development, even with preserved
LVEF. The potential roles of myocardial perfusion abnormalities in subjects with
cardiovascular risks, metabolic disease, and HF warrant further investigations.
In patients with CAD, a reduced CFR was shown to have prognostic implica-
tions, being a more sensitive predictor for cardiac death than was reduced left
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ventricular ejection fraction (LVEF). CFR in patients with CAD was found to be
also reduced in areas supplied by non-stenotic vessels, suggesting a microvascular
component. A recent study showed an association between global CFR and major
adverse cardiovascular events (MACE) independently of angiographic CAD prog-
nostic index (CADPI) [4]. This may attribute to diffuse atherosclerosis or micro-
vascular dysfunction. In addition, global CFR also modified the effect of coronary
revascularization in terms of event-free survival. These emphasize the utility of
cardiac PET in patient risk stratification and the role in decision-making for
coronary revascularization.
13.1.2 Transplant Vasculopathy
Cardiac allograft vasculopathy (CAV) is one of the leading causes of late mortality
after heart transplantation. It is characterized by the diffuse concentric intima
thickening of both epicardial and intramyocardial arteries, which is difficult to be
assessed by traditional coronary angiogram. Intravascular ultrasound (IVUS) has
been proposed to be the most sensitive method for diagnosis of early CAV. Due to
the progressive and diffuse process involving the epicardial and microvascular
coronary system, traditional stress myocardial perfusion SPECT frequently under-
estimates disease severity and extent in patients with CAV. With the absolute-
quantitative nature, PET provides a noninvasive way to deal with this problem. A
good correlation was observed between plaque burden as determined by IVUS and
CFR as assessed by 13N-ammonia PET in recipients with normal coronary angiog-
raphy findings. Quantitative measurement of myocardial flow using dynamic 13N-
ammonia PET is thus clinically feasible [5]. A recent study enrolled
140 posttransplant recipients with median follow-up of 18.2 months; the relative
perfusion defects, mean myocardial flow reserve, and mean stress MBF using
dipyridamole rubidium-82 PET were significant predictors of adverse outcome [6].
13.2 Sympathetic Innervation
Neurohormonal activation is considered as a compensatory mechanism in HF
and maintains perfusion to the heart, yet in the meanwhile is also responsible for
the progression of HF. From a long-term point of view, it is associated with
cardiac remodeling, progressive impairment of ventricular function, symptoms,
and lethal arrhythmia. Despite their critical role in regulation of the heart, local
neurohormonal statuses of patients are not routinely and closely monitored in
clinical practice. Innervation imaging may provide prognostic information as well
as guide selection of therapies. Both a decreased cardiac [123I]-meta-iodobenzyl-
guanidine (MIBG) activity and an increased washout rate are indicative of a poor
prognosis in patients with chronic heart failure [7]. Several PET tracers, including
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[11C]-meta-hydroxyephedrine (HED), a norepinephrine analog, and [11C]-
CGP12177, a beta-adrenoceptor antagonist, not only can be used to visualize global
but also regional defects in myocardial sympathetic innervation. A pilot study
enrolled 10 patients with dilated cardiomyopathy who underwent PET with [11C]-
HED before, acutely and 3 months after cardiac resynchronization (CRT) [8]. It
showed CRT improves cardiac sympathetic nerve activity in responders and seems
to be more effective in those with functionally preserved neuroautonomic system.
Decreased cardiac beta-adrenoceptor density measured by [11C]-CGP12177
PET was observed in a study of patients with nonischemic cardiomyopathy. In
addition the receptor density was significantly correlated with systolic function
[9]. Receptor density correlated with [123I]-MIBG washout rate and delayed heart-
to-mediastinum (H/M) ratio, but not early H/M ratio. Another study showed that
reduced myocardial beta-adrenoceptor density measured by [11C]-CGP12177 early
after myocardial infarction is associated with the incidence of congestive heart
failure on long-term follow-up [10]. Besides [11C]-labeled tracers, [18F]-N-
[3-Bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (LMI1195), an 18F-labeled ana-
log of [123I]-MIBG SPECT agent, is a new PET tracer retained in the heart through
the norepinephrine transporter (NET) and allowing evaluation of the cardiac sym-
pathetic neuronal function by PET imaging [11–13].
13.3 Noninvasive Assessment of Myocardial Metabolism
13.3.1 Myocardial Viability
Myocardial viability, the evaluation of dysfunctional but viable myocardium, can
be assessed by several imaging techniques. In conjunction with dobutamine, con-
tractile reserve can be evaluated by either echocardiography or cardiac magnetic
resonance imaging (MRI). Delayed contrast-enhanced (DCE) MRI and contrast-
enhanced CT can assess scar tissue. Myocardial perfusion SPECT evaluates either
cell membrane or mitochondria integrity. [18F]-fluorodeoxyglucose (FDG) can be
used to assess glucose metabolism and to differentiate the hibernating myocardium
from scar tissue. Dual-isotope simultaneous acquisition (DISA) viability testing,
the combination of [99mTc]-sestamibi and [18F]-FDG SPECT, provides more accu-
rate prediction of post-revascularization functional recovery than thallium-201
[14]. PET using FDG remains the most reliable and noninvasive tool to assess
myocardial viability [15] and tends to replace Tl-201 SPECT imaging in centers
equipped with a PET/CT camera.
For patients with CAD-associated chronic LV dysfunction, noninvasive detec-
tion of myocardial viability is crucial for decision-making of the treatment. Myo-
cardial viability imaging can be used to inform the often difficult clinical decision
regarding revascularization in patients with CAD and left ventricular systolic
dysfunction, providing data on the potential benefit to balance against the known
risks [15]. FDG PET has a higher sensitivity than DCE MRI, but comparable
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specificity, in predicting functional recovery [16]. The post hoc subgroup analysis
of the PET and Recovery Following Revascularization (PARR-2) trial suggested
that FDG PET-guided management reduces the composite of cardiovascular events
in patients with ischemic cardiomyopathy in a center with an experienced imaging
team [17].
Despite that several studies have emphasized the utility of viability imaging in
identifying patients who may benefit from revascularization, a recent meta-analysis
shows confusing results [18]. Patients with viable myocardium appear to benefit
from revascularization, but the same benefits were observed in patients without
viable myocardium. Some suggested this might be resulted from mixed traditional
(SPECT and dobutamine echocardiography) and the advanced (MRI and PET)
imaging techniques, but this was still not conclusive [19, 20]. A large prospective
randomized trial regarding Alternative Imaging Modalities in Ischemic Heart
Failure (AIMI-HF) has conducted in 2013 [21], which will complement the results
of the Surgical Treatment for Ischemic Heart Failure (STICH) viability substudy
and the PET and PARR-2 trial to answer this unsolved issue.
13.3.2 Cardiac Efficiency
[11C]-acetate, a well-known myocardial PET tracer, is directly metabolized into
[11C]-acetyl-CoA in mitochondria and enters the Krebs cycle. [11C]-acetate PET
imaging provides noninvasive and reproducible measurements of cardiac oxidative
metabolism (MVO2) [22]. Heterogeneously decreased oxidative metabolism was
observed in patients with ischemic and nonischemic cardiomyopathy [23]. In
chronic HF MI porcine model, myocardial perfusion and oxygen consumption in
the remote non-infarcted myocardium were preserved in HF pigs as compared to
controls. Global LV work and efficiency were significantly lower in HF than
controls and were associated with increased wall stress [24]. It can also be used
to evaluate cardiac efficiency under variable conditions, especially after treatments
of heart failure. Surgical intervention with LV volume reduction and mitral regur-
gitation correction significantly improved cardiac efficiency in patients with
end-stage heart failure, which is observed in both nonischemic and ischemic
etiologies [25].
On the other hand, myocardial oxygen metabolism was increased in patients
with aortic stenosis (AS), which was decreased after aortic valve replacement
[26]. It is suggested that the increased myocardial oxidative metabolism in AS
was largely attributable to the pressure overload of the left ventricle and normalized
after unload.
In a study of diastolic heart failure patients, decreased cardiac efficiency is
associated with increased LV filling pressure but does not primarily cause diastolic
dysfunction or diastolic heart failure in normal hearts [27]. They suggest that
improvement of cardiac efficiency may be a target for the treatment of heart failure
with preserved ejection fraction (HFpEF).
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13.3.3 Cardiac Resynchronization Therapy (CRT)
CRT can correct cardiac dyssynchrony and augment LV systolic function. PET is
the only noninvasive imaging technique that can provide information on alternations
of myocardial blood flow, glucose utilization, and oxygen consumption. [11C]-
acetate PET can also be used to evaluate the efficacy of CRT in patients with severe
heart failure [8, 28–31]. CRT could improve cardiac systolic function, but global
resting MBF and global MVO2 are not always altered by CRT, even under stress
condition [28]. A more homogeneous myocardial glucose uptake was observed,
which implies CRTmay induce a more balanced wall stress and energy requirement.
Another study demonstrated that decreased oxygen consumption was observed in
patients showing good response to CRT. The decrease in oxygen consumption
assessed by PET in the early period after CRT is useful to predict improvement of
cardiac function and major cardiac events during the first year of follow-up [31].
13.3.4 Chemotherapy-Related Heart Failure
[11C]-acetoacetate, a ketone body tracer, is expected to have some similarities to
[11C]-acetate. In mitochondria, acetoacetate is first converted into acetoacetyl-CoA
and then into acetyl-CoA. In cytoplasm, acetoacetate can also be directly incorpo-
rated into the lipogenesis pathway. Contrary to [11C]-acetate and other MBF PET
tracers, [11C]-acetoacetate together with dynamic gated PET imaging was able to
identify doxorubicin-induced heart failure at an early stage in a resting state. Thus,
[11C]-acetoacetate is promising for the assessment of cardiomyopathy [32].
13.3.5 Metabolic Therapy
Heart failure severity, substrate availability, hormonal status, and coexisting insulin
resistance contribute to the metabolic change. Optimizing myocardial energy
metabolism has been studied as a novel form of therapy [33]. Metabolic therapy
is a promising new avenue for the treatment of heart failure. Suitable targets for
therapy include substrate utilization, oxidative phosphorylation, and the availability
of high-energy phosphates [34].
Insulin resistance is a recognized phenomenon leading to heart failure. The
change in myocardial metabolism can be visualized using PET with metabolic
tracers. A prospective study utilized [15O]-water, [11C]-acetate, [11C]-glucose, and
[11C]-palmitate PET studies and found that obesity and gender independently
modulate MBF and MVO2. Moreover, gender and obesity may interact in
predicting myocardial glucose uptake and insulin sensitivity [35]. FDG PET can
also be used in evaluation of the effect of therapy on glucose metabolism. In a
transgenic mice model, G protein-coupled receptor kinase 2 inhibition delays the
reduction in glucose uptake and protects insulin signaling in the heart, preserving
cardiac dimension and function [36].
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13.4 Molecular Imaging Approaches of Cardiac
Remodeling
13.4.1 Imaging of Matrix Metalloproteinases
The matrix metalloproteinases (MMPs) play a role in physiologic extracellular
matrix (ECM) turnover and response to cardiac disease. During the progression
of HF, the level of MMPs is increased. The excessive degradation of ECM may
result in wall thinning, dilatation, and heart failure. Post-MI myocardial LV
remodeling is also associated with changes within the myocardial extracellular
matrix and often leads to heart failure. MI results in the activation of the renin-
angiotensin-aldosterone system, which in turn results in the activating of MMPs
within the heart. Molecular imaging of MMPs has the potential to allow early and
serial evaluation of underlying alterations that accompany progression of LV
remodeling [37]. The activation of MMPs in infarcted murine myocardium can
be imaged by [111In]- and [99mTc]-labeled single-photon ligands [38]. Several PET
tracers have also been synthesized [39]. However, to date there are only limited
publications, especially in the field of HF.
13.4.2 Angiogenesis
Angiogenesis occurs in response to ischemia and inflammation being part of the
healing process after ischemic tissue injury. [18F]-galacto-RGD allows noninvasive
imaging of the expression of αvβ3 integrin that is highly expressed in the endothe-
lium of angiogenic vessels. Noninvasive imaging using [18F]-galacto-RGD PET
appears promising for the monitoring of therapies aiming to stimulate angiogenesis
in ischemic heart disease and preventing the development of HF [40].
13.4.3 Myocardial Inflammation
FDG PET may be useful in the study of inflammatory process since inflammatory
cells accumulate glucose. However, a recent study showed some limitations to
study the inflammatory process after myocardial infarction even when active uptake
of FDG in normal myocardial tissue is suppressed. In the presence of large region of
microvascular obstruction, FDG may not reliably and accurately represent the
degree of inflammatory cell activity. Even in areas without microvascular obstruc-
tion, the degree of inflammation may be underestimated or even overestimated [41].
Besides the usefulness as a molecular target for neuroendocrine tumor imaging,
some of the somatostatin receptors are also expressed by activated macrophage. A
recent animal study compared [68Ga]-citrate, [68Ga]-DOTATATE, and [18F]-FDG
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in a postinfarction mouse model [42]. They conclude that FDG with myocardial
suppression is the most practical imaging marker of postinfarction inflammation.
However, there are also some studies in human that emphasize the usefulness of the
somatostatin receptor imaging in the assessment of sarcoidosis [43] and infarction
[44]-related myocardial inflammation. Compared with the nonspecific FDG, this is
a new potential biomarker that may be useful in evaluation of myocardial inflam-
mation and predicting cardiac remodeling and progression toward heart failure.
13.5 Conclusions
Advances in the application of cardiac PET may play an increasingly critical role in
diagnosis, prognosis, and clinical treatment of cardiovascular diseases. Molecular
imaging approaches using PET could evaluate myocardial pathophysiology at
different stages of HF. It further provides insights on the HF preventive strategies,
tracking patients’ clinical status, novel drug therapies, expanding indications for HF
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Fig. 13.1 Potential roles of PET imaging in different stages of American College of Cardiology
(ACC)/American Heart Association (AHA) classification of heart failure. CAV cardiac allograft
vasculopathy, CFR coronary flow reserve, HRQOL health-related quality of life, ICD implantable
cardioverter defibrillator, MBF myocardial blood flow, LV left ventricular, LVAD left ventricular
assist device
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